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Irrespective of histological sub-type, it is axiomatic that
further improvements in the chemotherapy of non-Hodgkin's
lymphomas (NHL) require either the development of new
effective drugs or the better use of existing agents. By
convention, a cytotoxic drug is considered to have activity
against a particular tumour type if objective decreases in the
size of measurable disease are observed in a proportion of
patients. In some instances however an apparently inactive
drug may interact with its appropriate intracellular target
but fail to produce any clinically detectable effect.
'Subclinical responses' might be of potential benefit if the
drug were to be combined with a second agent with which it
acted synergistically, especially if this potentiation were
tumour-specific.
Recently there has been a resurgence of interest in 5-
fluorouracil (5-FU), with evidence that its action may be
markedly potentiated by combination for example with
methotrexate (Bertino et al., 1977) or cis-platin (Kish et al.,
1984). Although 5-FU is considered an inactive drug in the
treatment of NHL (Heidelberger, 1982), the total number of
patients treated and subsequently reported is small, and the
earlier literature does in fact show some responses (Ansfield
et al., 1962; Krivit & Bentley, 1960). It therefore seemed
timely to re-assess its single agent activity in the treatment of
NHL.
Both DNA and RNA synthesis can be inhibited by 5-FU
treatment, the former resulting from blockade of thymidylate
synthetase. In addition to conventional clinical criteria for
response, the ability of 5-FU to perturb DNA synthesis was
therefore assessed by using flow cytometry to measure the
cellular DNA content of sequential fine needle aspirates
from the tumour.
Four patients with end stage, drug resistant NHL were
treated with 5-FU, and their clinical details are summarised
in Table I. Two had diffuse large cell lymphoma, and two
well differentiated diffuse lymphocytic lymphoma. All had
measurable symptomatic disease, and despite numerous
previous courses of cytotoxic drugs expressed a desire to try
further chemotherapy and gave verbal informed consent for
multiple fine needle aspirates from tumour desposits.
Treatment comprised 5-FU, 1,000mgm2 day-1 given as a
continuous i.v. infusion for 4 days except in one patient (Al),
who received only a 3-day infusion because of pre-existing
thrombocytopaenia.
In addition to the size of tumour deposits, measurements
were made of cellular DNA content using flow cytometry.
Fine needle (23 gauge) aspirates were taken from accessible
sites pre-treatment. In three cases an adequate amount of
material for DNA flow cytometry (i.e. 105-106 nucleated
cells) was obtained. The fourth patient (Al) had multiple
lymph nodes which were too small for satisfactory fine
needle aspiration, but also had a peripheral blood lympho-
cytosis (absolute lymphocyte count 6 x 1001-1) and lymph
node histology which showed well differentiated diffuse
lymphocytic lymphoma. Peripheral blood was therefore used
instead for flow cytometry. In all cases material was
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obtained before and daily during the 5-FU infusion. The
cells were dispersed into 2ml RPMI 1640 tissue culture medium
by gently syringing through the 23 gauge needle used for
aspiration, and the sample stained using ethidium bromide
and mithramycin as previously described (Taylor, 1980).
Chick red blood cells were added as an internal biological
standard. Cellular DNA content was measured using an
ICP 22 Flow Cytometer (Ortho Instruments, Westwood, Ma.,
USA), the results being expressed as frequency-distribution
histograms (Figure 1), and the percentage of S-phase cells
was assessed planimetrically using a computer program
(Milthorpe, 1980).
As expected from previous experience using this regimen,
treatment was well tolerated. One patient (WW) had a
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Figure 1 DNA histograms of tumour cells pre and post 5-FU.
Patients Al and PA had diploid tumours, with G cells
represented by a peak in channel number 50, G2+M in channel
number 100 and S-phase lying between these peaks. S-phase is
shown expanded in PA (dotted line). Patients WW and ME had
aneuploid tumours, the tumour G, peak lying in approximately
channel number 100. The left-most peak, with the lowest DNA
content, is from an internal marker (chick red blood cells), and
lies in channel number 17. C.V.=coefficient of variance of the
diploid GI peak.
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Table I Patient characteristics and response to 5-fluorouracil
S-phase
cells Suirvival
Prior Response fionm 5-FU
Paltient Age Sex Sub-tYpe treatment to5-FU Pre Post treatment
WW 57 M DHL' (1) CHOP+MTX, MRd 20.3 39.8 2 weeks
(2) Cis DDP+VP16, (3) COP
ME 47 F PDNLb PDe 29.2 22.8 2 months
DHL (1) Chlor+Pred, (2) Cyclo
(3) MTX, (4) Adria, VCR,
Bleo+ Pred
Al 68 M DWDLC (1) Chlor+Pred, (2) COP PD 2.4 21.1 2+ months
PA 58 F DWDL (1) COP, (2) Chlor+Pred, PD 4.3 8.9 4 months
(3) CCNU, Bleo+Pred
'Diffuse histiocytic lymphoma; bPoorly differentiated nodular lymphocytic lymphoma; cDiffuse well differentiated
lymphoma; dMeasurable response; 'Progressive disease.
measurable diminution in the size of s.c. lymphoma deposits
which did not satisfy the criteria for partial response and
which lasted for one week only following the completion of
the 4-day 5-FU infusion. Another patient (ME) experienced
improvement in pain caused by retroperitoneal lymph node
involvement, but again this lasted for only one week. Neither
of the patients with 'indolent' NHL histology (PA and Al)
showed any clinically apparent response to treatment. In
contrast, three patients (WW, Al, PA) had evidence of
response as assessed using DNA flow cytometry, which
showed build up of cells in early S-phase by about day 3 of
the 4-day infusion. This implies that the rate of DNA
synthesis was reduced, and would be fully consistent with
thymidylate synthetase inhibition. The effect appeared to be
most pronounced in patient WW, who also showed a
transient clinical response. It should be noted, however, that
this patient's tumour had a tetraploid DNA content, as
shown by reference to the chick red blood cell marker, and
the tumour cell population was therefore studied without the
dilutional effect of diploid normal host cells, in contrast to
the two low grade lymphomas (patients Al and PA). 5-FU
can also inhibit RNA synthesis (Heidelberger, 1982), but
although RNA content can be measured using flow
cytometry (Traganos et al., 1977) the method used here is
not suited for study of this particular effect.
Although the study was curtailed because these results do
not suggest a role for single agent 5-FU treatment of drug
resistant NHL, it raises the question of whether a clinically
measurable reduction in the size of tumour deposits is the
only biologically relevant criterion for 'response', since in
three of the four patients studied here the target enzyme was
apparently inhibited despite the lack of a significant
reduction in tumour cell mass. It is possible that this effect
of 5-FU on DNA synthesis in NHL could potentiate other
cytotoxic drugs such as methotrexate. and that the drug
might therefore be suitable for inclusion in combination
chemotherapy regimens.
Previous studies using DNA flow cytometry to measure
cell cycle phase distribution in sequential fine needle
aspirates have shown pronounced effects both in patients
with small cell anaplastic lung cancer receiving multi-agent
chemotherapy (Vindelov et al., 1982), and also in human
breast cancer xenografts undergoing hormonal manipulations
(Brunner et al., 1983). Apart from minor local discomfort
and occasional haematoma formation, fine needle aspiration
from superficial tumour masses is safe, non-traumatic and in
most instances yields sufficient material for DNA flow
cytometry. Because it gives rapid and potentially useful
information about the action of cytotoxic drugs in man it
deserves further study in patients with accessible deposits
undergoing treatment with single agents.
Patients ME, Al and PA were under the care of Drs D. Raghavan.
R. Fox and A. Coates, respectively, and I am grateful for their
enthusiastic co-operation.
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